Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026)
Century Therapeutics' (IPSC) quarterly Income from Continuing Operations came in at 90912000.0 in Q1 2026, down 218.75% year-on-year from 76560000.0 in Q1 2025, and down 852.26% on a QoQ basis from 9547000.0 in Q4 2025.
Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has 7 years of Income from Continuing Operations data on file, last reported at 90912000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 218.75% year-over-year to 90912000.0 in Q1 2026; TTM through Mar 2026 was 167422000.0, a 677.04% decrease from a year earlier, with the FY2025 full-year figure at 2070000.0, up 101.64% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 90912000.0, down from 9547000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IPSC reached as high as 76560000.0 in Q1 2025 and fell as low as 90912000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 28507941.18 across 5 years, with a median of 31682000.0 in 2022.
- Across the five-year window, Income from Continuing Operations jumped 372.82% in 2025 and slumped 218.75% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 31682000.0 in 2022, then decreased by 24.35% to 39398000.0 in 2023, then climbed by 9.45% to 35673000.0 in 2024, then surged by 73.24% to 9547000.0 in 2025, then slumped by 852.26% to 90912000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 90912000.0 in Q1 2026, 9547000.0 in Q4 2025, and 34422000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Century Therapeutics | 406.30 Mn | 271.49 Mn | - | -90.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.91 Mn |
| Dec 31, 2025 | -9.55 Mn |
| Sep 30, 2025 | -34.42 Mn |
| Jun 30, 2025 | -32.54 Mn |
| Mar 31, 2025 | 76.56 Mn |
| Dec 31, 2024 | -35.67 Mn |
| Sep 30, 2024 | -31.23 Mn |
| Jun 30, 2024 | -31.21 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -39.40 Mn |
| Sep 30, 2023 | -32.72 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -31.68 Mn |
| Sep 30, 2022 | -30.75 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -37.51 Mn |
| Dec 31, 2021 | -28.15 Mn |
| Sep 30, 2021 | -26.01 Mn |
| Jun 30, 2021 | -23.27 Mn |